{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:28:53Z","timestamp":1790998133707,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03592"],"award-info":[{"award-number":["JP20H03592"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00415-023-11667-5","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T09:03:13Z","timestamp":1679302993000},"page":"3413-3423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dysautonomia associated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"270","author":[{"given":"Toshiki","family":"Tezuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Okuzumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Mitsuboshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Aragane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-4574","authenticated-orcid":false,"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"1","key":"11667_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7(1):306","journal-title":"J Immunother Cancer"},{"issue":"11","key":"11667_CR2","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ et al (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93(11):e1093\u2013e1103","journal-title":"Neurology"},{"issue":"4","key":"11667_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00262-021-03053-9","volume":"71","author":"M Seki","year":"2022","unstructured":"Seki M, Kitano S, Suzuki S (2022) Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother 71(4):769\u2013775","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"11667_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","volume":"268","author":"K Okada","year":"2021","unstructured":"Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, Oki K, Nakahara J, Suzuki S (2021) Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol 268(2):680\u2013688","journal-title":"J Neurol"},{"issue":"7","key":"11667_CR5","doi-asserted-by":"publisher","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, Betof Warner A, Brastianos PK, Cho TA, Clardy SL et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9(7):e002890","journal-title":"J Immunother Cancer"},{"issue":"5","key":"11667_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87(5):659\u2013669","journal-title":"Ann Neurol"},{"issue":"14","key":"11667_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D, H\u00f8jgaard JLS, Kondziella D (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92(14):663\u2013674","journal-title":"Neurology"},{"issue":"2","key":"11667_CR8","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","volume":"97","author":"V Nersesjan","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup LH, Kondziella D (2021) Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology 97(2):e191\u2013e202","journal-title":"Neurology"},{"issue":"16","key":"11667_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754\u2013766","journal-title":"Neurology"},{"issue":"4","key":"11667_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.amjmed.2018.09.027","volume":"132","author":"P Novak","year":"2019","unstructured":"Novak P (2019) Autonomic disorders. Am J Med 132(4):420\u2013436","journal-title":"Am J Med"},{"issue":"3","key":"11667_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10286-019-00611-1","volume":"29","author":"EP Golden","year":"2019","unstructured":"Golden EP, Vernino S (2019) Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clin Auton Res 29(3):277\u2013288","journal-title":"Clin Auton Res"},{"key":"11667_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102403","volume":"108","author":"S Nakane","year":"2020","unstructured":"Nakane S, Mukaino A, Higuchi O, Yasuhiro M, Takamatsu K, Yamakawa M, Watari M, Tawara N, Nakahara KI, Kawakami A et al (2020) A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun 108:102403","journal-title":"J Autoimmun"},{"issue":"6","key":"11667_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ana.10556","volume":"53","author":"CM Klein","year":"2003","unstructured":"Klein CM, Vernino S, Lennon VA, Sandroni P, Fealey RD, Benrud-Larson L, Sletten D, Low PA (2003) The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53(6):752\u2013758","journal-title":"Ann Neurol"},{"issue":"9","key":"11667_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/CJI.0000000000000381","volume":"44","author":"G Montes","year":"2021","unstructured":"Montes G, Duval F, Eldani C, Amico S, G\u00e9rard E, Dutriaux C, Herran C, Poullenot F, Sole G, Carla L et al (2021) Esophageal achalasia induced by ipilimumab and nivolumab combination: a rare neurological manifestation of immune-related autonomic neuropathy. J Immunother 44(9):348\u2013350","journal-title":"J Immunother"},{"issue":"4","key":"11667_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/CND.0000000000000230","volume":"20","author":"C Yuen","year":"2019","unstructured":"Yuen C, Kamson D, Soliven B, Kramer C, Goldenberg F, Rezania K (2019) Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with nivolumab. J Clin Neuromuscul Dis 20(4):194\u2013199","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"11667_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-018-0396-9","volume":"6","author":"J Appelbaum","year":"2018","unstructured":"Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H, Nghiem P, Kapur RP, Thompson JA, Bhatia S (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6(1):82","journal-title":"J Immunother Cancer"},{"issue":"5","key":"11667_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CJI.0000000000000167","volume":"40","author":"WuW Kelly","year":"2017","unstructured":"Kelly WuW, Broman KK, Brownie ER, Kauffmann RM (2017) Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunother 40(5):196\u2013199","journal-title":"J Immunother"},{"key":"11667_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","volume":"45","author":"Y Gu","year":"2017","unstructured":"Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G (2017) Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 45:14\u201317","journal-title":"J Clin Neurosci"},{"issue":"6","key":"11667_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2326-6066.CIR-15-0035","volume":"3","author":"RM Conry","year":"2015","unstructured":"Conry RM, Sullivan JC, Nabors LB 3rd (2015) Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 3(6):598\u2013601","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"11667_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ (2013) A severe case of ipilimumab-induced guillain-barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36(1):77\u201378","journal-title":"J Immunother"},{"issue":"2","key":"11667_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/CJI.0b013e318193a206","volume":"32","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Huber BR, Upton MP, Thompson JA (2009) Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 32(2):203\u2013205","journal-title":"J Immunother"},{"issue":"1","key":"11667_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s40425-019-0748-0","volume":"7","author":"CA Gao","year":"2019","unstructured":"Gao CA, Weber UM, Peixoto AJ, Weiss SA (2019) Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. J Immunother Cancer 7(1):262","journal-title":"J Immunother Cancer"},{"issue":"1","key":"11667_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39\u201351","journal-title":"J Thorac Oncol"},{"issue":"4","key":"11667_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10286-017-0425-7","volume":"27","author":"DS Goldstein","year":"2017","unstructured":"Goldstein DS, Cheshire WP Jr (2017) The autonomic medical history. Clin Auton Res 27(4):223\u2013233","journal-title":"Clin Auton Res"},{"issue":"3","key":"11667_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118312","volume":"10","author":"S Nakane","year":"2015","unstructured":"Nakane S, Higuchi O, Koga M, Kanda T, Murata K, Suzuki T, Kurono H, Kunimoto M, Kaida K, Mukaino A et al (2015) Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS ONE 10(3):e0118312","journal-title":"PLoS ONE"},{"issue":"11","key":"11667_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","volume":"59","author":"YK Nakao","year":"2002","unstructured":"Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, Yoshimura T, Tsujihata M, Eguchi K (2002) Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59(11):1773\u20131775","journal-title":"Neurology"},{"key":"11667_CR27","unstructured":"FDA adverse event reporting system (FAERS). Quarterly data extract files. [https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html]. Accessed 12 July 2022"},{"issue":"8","key":"11667_CR28","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/cid\/ciac128","volume":"75","author":"M Chuma","year":"2022","unstructured":"Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K et al (2022) Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis. Clin Infect Dis 75(8):1416\u20131422","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11667_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","volume":"44","author":"C Wei","year":"2022","unstructured":"Wei C, Liu Y, Jiang A, Wu B (2022) A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on food and drug administration adverse event reporting system data. Int J Clin Pharm 44(3):709\u2013716","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"11667_CR30","doi-asserted-by":"publisher","first-page":"10709","DOI":"10.1038\/s41598-021-90108-7","volume":"11","author":"B Wu","year":"2021","unstructured":"Wu B, Hu Q, Tian F, Wu F, Li Y, Xu T (2021) A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep 11(1):10709","journal-title":"Sci Rep"},{"key":"11667_CR31","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). [https:\/\/www.meddra.org\/how-to-use\/support-documentation\/japanese]. Accessed 12 July 2022"},{"issue":"8","key":"11667_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"11667_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41582-020-0321-y","volume":"16","author":"JK Karimy","year":"2020","unstructured":"Karimy JK, Reeves BC, Damisah E, Duy PQ, Antwi P, David W, Wang K, Schiff SJ, Limbrick DD Jr, Alper SL et al (2020) Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets. Nat Rev Neurol 16(5):285\u2013296","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"11667_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangu\u00e9 T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157\u2013165","journal-title":"Lancet Neurol"},{"issue":"6","key":"11667_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.braindev.2015.12.009","volume":"38","author":"I Kuki","year":"2016","unstructured":"Kuki I, Kawawaki H, Okazaki S, Hattori Y, Horino A, Higuchi O, Nakane S (2016) Autoimmune autonomic ganglionopathy in a pediatric patient presenting with acute encephalitis. Brain Dev 38(6):605\u2013608","journal-title":"Brain Dev"},{"issue":"10","key":"11667_CR36","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp.2003.025171","volume":"75","author":"PM Candler","year":"2004","unstructured":"Candler PM, Hart PE, Barnett M, Weil R, Rees JH (2004) A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 75(10):1411\u20131415","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"11667_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archneurol.2009.341","volume":"67","author":"B Giometto","year":"2010","unstructured":"Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G (2010) Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 67(3):330\u2013335","journal-title":"Arch Neurol"},{"issue":"4","key":"11667_CR38","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8(4):e1014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"20","key":"11667_CR39","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.2169\/internalmedicine.50.5439","volume":"50","author":"K Shimizu","year":"2011","unstructured":"Shimizu K, Yoshii Y, Watanabe S, Hosoda C, Takagi M, Tominaga T, Kawaishi M, Kuwano K (2011) Neurally mediated syncope associated with small cell lung cancer: a case report and review. Intern Med 50(20):2367\u20132369","journal-title":"Intern Med"},{"issue":"1","key":"11667_CR40","first-page":"77","volume":"4","author":"HY Chen","year":"2012","unstructured":"Chen HY (2012) Recurrent syncope as initial symptom in apical intrathoracic tumor. J Clin Med Res 4(1):77\u201380","journal-title":"J Clin Med Res"},{"issue":"5","key":"11667_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3892\/mco.2016.1032","volume":"5","author":"X Jiang","year":"2016","unstructured":"Jiang X, Zhao J, Bai C, Xu E, Chen Z, Han Y (2016) Small-cell lung cancer with recurrent syncope as the initial symptom: a case report and literature review. Mol Clin Oncol 5(5):545\u2013549","journal-title":"Mol Clin Oncol"},{"key":"11667_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-684X-11-3","volume":"11","author":"CA Stone","year":"2012","unstructured":"Stone CA, Kenny RA, Nolan B, Lawlor PG (2012) Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessment. BMC Palliat Care 11:3","journal-title":"BMC Palliat Care"},{"issue":"1","key":"11667_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10286-017-0493-8","volume":"28","author":"EP Golden","year":"2018","unstructured":"Golden EP, Bryarly MA, Vernino S (2018) Seronegative autoimmune autonomic neuropathy: a distinct clinical entity. Clin Auton Res 28(1):115\u2013123","journal-title":"Clin Auton Res"},{"issue":"1","key":"11667_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 145(1):1\u20139","journal-title":"J Neurooncol"},{"issue":"1","key":"11667_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11667-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T16:02:13Z","timestamp":1686758533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11667-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["11667"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11667-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ToT, SO, CN, TI, SI, SM, YK, TsT, MS, NM, NA, JN, SH, and SN: declare no competing interests. SS: is a consultant\/advisory board member on neurologic side effects for Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Chugai, and Astra Zeneca. Outside of the submitted work, SS reports personal fees from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Chugai, and Astra Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee for Human Research of the Keio University School of Medicine and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All the subjects gave their informed consent (#N20170237).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}